MedTrace Logo

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03038022 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-12-23

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).

Conditions

  • Heterozygous Familial Hypercholesterolemia

Interventions

DRUG

MGL-3196 (resmetirom)

Oral

DRUG

Placebo

Oral

Sponsors & Collaborators

  • Madrigal Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rebecca Taub, MD · Madrigal Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-23
Primary Completion
2018-01-15
Completion
2018-01-15
FDA Drug
Yes

Countries

  • Denmark
  • Netherlands
  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038022 on ClinicalTrials.gov